An Open Label, Phase II Study Assessing Potential Predictive Tumor Markers in Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor Treated With FOLFOX Plus Panitumumab as First-line Therapy
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2016
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms PULSE
- 07 Jun 2017 Biomarkers information updated
- 11 Oct 2016 Results of a subgroup analysis in the RAS/BRAF WT patients, presented at the 41st European Society for Medical Oncology Congress.
- 21 Feb 2015 Status changed from active, no longer recruiting to completed as reported by EudraCT record.